Trovagene Inc. (NASDAQ:TROV) – Investment analysts at Cantor Fitzgerald boosted their FY2016 earnings estimates for shares of Trovagene in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst B. Brokmeier now anticipates that the brokerage will post earnings per share of ($1.39) for the year, up from their previous forecast of ($1.40). Cantor Fitzgerald currently has a “Buy” rating and a $7.00 price target on the stock.
Several other brokerages also recently issued reports on TROV. Zacks Investment Research downgraded shares of Trovagene from a “buy” rating to a “hold” rating in a research report on Tuesday, September 20th. Maxim Group raised their target price on shares of Trovagene from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Finally, Piper Jaffray Cos. set a $4.00 target price on shares of Trovagene and gave the stock a “hold” rating in a report on Friday, August 5th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Trovagene has an average rating of “Hold” and a consensus target price of $7.04.
Shares of Trovagene (NASDAQ:TROV) traded down 0.88% on Thursday, hitting $4.49. The stock had a trading volume of 47,100 shares. The firm’s market capitalization is $135.36 million. Trovagene has a 12-month low of $2.85 and a 12-month high of $7.18. The company has a 50 day moving average of $4.89 and a 200-day moving average of $4.92.
Trovagene (NASDAQ:TROV) last announced its earnings results on Thursday, August 4th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.03. Trovagene had a negative return on equity of 80.13% and a negative net margin of 8,495.00%.
Several hedge funds have recently bought and sold shares of TROV. First Heartland Consultants Inc. bought a new stake in Trovagene during the second quarter worth $103,000. Rhumbline Advisers boosted its stake in Trovagene by 39.3% in the second quarter. Rhumbline Advisers now owns 39,171 shares of the company’s stock worth $177,000 after buying an additional 11,044 shares during the last quarter. Princeton Capital Management Inc. bought a new stake in Trovagene during the second quarter worth $314,000. BlackRock Investment Management LLC boosted its stake in Trovagene by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 113,232 shares of the company’s stock worth $513,000 after buying an additional 5,964 shares during the last quarter. Finally, Advisor Group Inc. bought a new stake in Trovagene during the second quarter worth $520,000. 31.06% of the stock is currently owned by hedge funds and other institutional investors.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.